The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Srijana Bharat Sharma & Others
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals promoters have converted 3,00,000 convertible warrants into equity shares of Rs. 10 face value, originally allotted via preferential issue on July 17, 2025. Srijana Bharat Sharma (Promoter) received 2,00,000 shares while Anagh Bharat Sharma (Promoter Group) received 1,00,000 shares. As a result, the company's equity share capital expanded from Rs. 4.84 crore to Rs. 5.91 crore (48,36,500 to 59,11,500 shares). Total promoter group holding now stands at 30,09,550 shares, representing 50.91% of the diluted share/voting capital of the company.
This is a routine disclosure confirming promoter group's conversion of warrants they were previously allotted. It increases the company's share capital and dilutes non-promoter shareholders marginally, but signals continued promoter commitment since they chose to convert rather than let warrants lapse.